CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2014 Society for Neuro-Oncology Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Raizer Discusses Proton Therapy for Glioma
Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma
Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma
Oncology Conference Articles
Experts Discuss Immunotherapy's Potential in Neuro-Oncology
Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.
Oncolytic Virus Shows Early Promise in Glioma
The oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients, according to phase I research presented at the 2014 Society for Neuro-Oncology (SNO) Annual Meeting in Miami.
Survival Improvement With NovoTTF Leads to Early End of Phase III Trial
Use of the NovoTTF system along with adjuvant temozolomide led to longer progression-free survival and overall survival in patients with glioblastoma.
Rindopepimut Leads to Improved PFS in Compassionate Use Study
The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.
Ceritinib Effective in Patients With Brain Metastases
The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.
Rindopepimut Plus Bevacizumab Shows Prolonged Survival in Recurrent Glioblastoma
The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.
Adding Lomustine to Bevacizumab Improves Outcomes in Recurrent Glioblastoma
The combination of bevacizumab and lomustine showed superior efficacy compared with either agent alone in patients with recurrent glioblastoma, warranting further study.
PCV Chemotherapy Plus Radiation Improves Survival in Low-Grade Glioma
The combination of radiation therapy with procarbazine, CCNU, and vincristine prolonged OS and PFS compared with radiation therapy alone in grade 2 glioma.
FDA Approvals in Cervical Cancer, Ovarian Cancer, and CLL, and More
Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma
Upfront Options Continue to Expand in Ovarian Cancer
Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL
Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.